Jusko WJ[au] - Search Results

Year	Number of Results
1965	1
1966	2
1967	3
1969	2
1970	6
1971	5
1972	11
1973	4
1974	6
1975	10
1976	11
1977	9
1978	15
1979	13
1980	10
1981	11
1982	14
1983	7
1984	19
1985	5
1986	10
1987	5
1988	11
1989	18
1990	11
1991	14
1992	10
1993	18
1994	23
1995	18
1996	7
1997	8
1998	22
1999	16
2000	4
2001	9
2002	12
2003	12
2004	13
2005	13
2006	14
2007	16
2008	22
2009	15
2010	15
2011	15
2012	16
2013	12
2014	8
2015	13
2016	8
2017	15
2018	13
2019	14
2020	12
2021	8

1

Applications of minimal physiologically-based pharmacokinetic models.

Cao Y, Jusko WJ. Cao Y, et al. Among authors: jusko wj. J Pharmacokinet Pharmacodyn. 2012 Dec;39(6):711-23. doi: 10.1007/s10928-012-9280-2. Epub 2012 Nov 23. J Pharmacokinet Pharmacodyn. 2012. PMID: 23179857 Free PMC article.

2

Transitioning from Basic toward Systems Pharmacodynamic Models: Lessons from Corticosteroids.

Ayyar VS, Jusko WJ. Ayyar VS, et al. Among authors: jusko wj. Pharmacol Rev. 2020 Apr;72(2):414-438. doi: 10.1124/pr.119.018101. Pharmacol Rev. 2020. PMID: 32123034 Free PMC article. Review.

3

Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug.

Conklin LS, Damsker JM, Hoffman EP, Jusko WJ, Mavroudis PD, Schwartz BD, Mengle-Gaw LJ, Smith EC, Mah JK, Guglieri M, Nevo Y, Kuntz N, McDonald CM, Tulinius M, Ryan MM, Webster R, Castro D, Finkel RS, Smith AL, Morgenroth LP, Arrieta A, Shimony M, Jaros M, Shale P, McCall JM, Hathout Y, Nagaraju K, van den Anker J, Ward LM, Ahmet A, Cornish MR, Clemens PR. Conklin LS, et al. Among authors: jusko wj. Pharmacol Res. 2018 Oct;136:140-150. doi: 10.1016/j.phrs.2018.09.007. Epub 2018 Sep 13. Pharmacol Res. 2018. PMID: 30219580 Free PMC article. Clinical Trial.

4

Journal editor's final report.

Jusko WJ. Jusko WJ. J Pharmacokinet Pharmacodyn. 2019 Dec;46(6):511-512. doi: 10.1007/s10928-019-09665-0. J Pharmacokinet Pharmacodyn. 2019. PMID: 31720983 No abstract available.

5

Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies.

Cao Y, Balthasar JP, Jusko WJ. Cao Y, et al. Among authors: jusko wj. J Pharmacokinet Pharmacodyn. 2013 Oct;40(5):597-607. doi: 10.1007/s10928-013-9332-2. Epub 2013 Aug 31. J Pharmacokinet Pharmacodyn. 2013. PMID: 23996115 Free PMC article.

6

Ampicillin.

Jusko WJ. Jusko WJ. J Am Pharm Assoc. 1975 Oct;15(10):591-4. doi: 10.1016/s0003-0465(16)34104-0. J Am Pharm Assoc. 1975. PMID: 1184921 No abstract available.

7

Dose equivalency evaluation of major corticosteroids: pharmacokinetics and cell trafficking and cortisol dynamics.

Mager DE, Lin SX, Blum RA, Lates CD, Jusko WJ. Mager DE, et al. Among authors: jusko wj. J Clin Pharmacol. 2003 Nov;43(11):1216-27. doi: 10.1177/0091270003258651. J Clin Pharmacol. 2003. PMID: 14551176 Clinical Trial.

8

Physiologically Based Pharmacokinetics of Dexamethasone in Rats.

Song D, Sun L, DuBois DC, Almon RR, Meng S, Jusko WJ. Song D, et al. Among authors: jusko wj. Drug Metab Dispos. 2020 Sep;48(9):811-818. doi: 10.1124/dmd.120.091017. Epub 2020 Jun 29. Drug Metab Dispos. 2020. PMID: 32601175

9

Interactions of Tofacitinib and Dexamethasone on Lymphocyte Proliferation.

Yu R, Li X, DuBois DC, Almon RR, Cao Y, Jusko WJ. Yu R, et al. Among authors: jusko wj. Pharm Res. 2020 May 26;37(6):105. doi: 10.1007/s11095-020-02827-7. Pharm Res. 2020. PMID: 32458079

10

Indirect pharmacodynamic models for responses with circadian removal.

Ayyar VS, Krzyzanski W, Jusko WJ. Ayyar VS, et al. Among authors: jusko wj. J Pharmacokinet Pharmacodyn. 2019 Feb;46(1):89-101. doi: 10.1007/s10928-019-09620-z. Epub 2019 Jan 29. J Pharmacokinet Pharmacodyn. 2019. PMID: 30694437 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results